[144] ANI Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

ANI Pharmaceuticals (ANIP) Form 144 notice discloses a proposed sale of 52,990 common shares through Merrill Lynch on NASDAQ with an aggregate market value of $4,618,063.56, and reports 21,688,772 shares outstanding. The filer indicates the shares were acquired on 11/19/2021 via a company buyout and are being sold as a compensatory payment. The filing also lists a recent sale by the same person: 47,010 common shares sold on 08/14/2025 for gross proceeds of $4,206,603.82. The notice includes the seller’s representation that they are not aware of undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Insider filing reports modest sale of ANIP shares; not obviously material to cap structure.

The Form 144 notifies the market of a proposed sale of 52,990 common shares valued at $4.62 million, against 21,688,772 shares outstanding, which implies the proposed sale equals a small fraction of total shares outstanding. The shares were acquired in 2021 via a company buyout and are characterized as a compensatory payment, indicating they likely resulted from corporate compensation arrangements. The filer also disclosed a prior sale of 47,010 shares on 08/14/2025 for $4.21 million. These disclosures are procedural and provide transparency about insider liquidity; they do not by themselves indicate a change in company operations or financial condition.

Corporate Governance Expert

TL;DR: Routine Rule 144 filing documenting insider disposition tied to compensation; governance disclosure intact.

The document fulfills Rule 144 notice requirements by identifying the broker, share count, acquisition date, and nature of acquisition (company buyout). The filing includes the seller’s attestation regarding material undisclosed information, which aligns with compliance norms. Because the transaction stems from compensatory arrangements and represents a relatively small share of the outstanding base, this appears to be a routine insider liquidity event rather than a governance red flag.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	Merrill Lynch 3455 Peachtree Road Atlanta GA 30326	52990	4618063.56	21688772	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/19/2021	Company Buyout	ANI Pharmaceuticals			52990	08/15/2025	compensatory payment

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Muthusamy Shanmugam 210 Main Street West Baudette MN 56623	common	08/14/2025	47010	4206603.82

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ANIP Form 144 disclose about the upcoming sale?

The filing discloses a proposed sale of 52,990 common shares via Merrill Lynch on NASDAQ with an aggregate market value of $4,618,063.56.

When were the shares being sold by ANIP insider acquired?

The shares were acquired on 11/19/2021 in a company buyout.

How many ANIP shares were outstanding per the filing?

The filing reports 21,688,772 shares outstanding.

Did the filer recently sell ANIP shares before this proposed sale?

Yes; the filing reports a sale of 47,010 common shares on 08/14/2025 for gross proceeds of $4,206,603.82.

What is the stated reason or nature of payment for the shares being sold?

The filing states the sale relates to a compensatory payment.